Search

Online shopping festivals have become powerful ways for major e-commerce platforms to conduct promotions. To explore the rule and hidden information of the change of users’ attention to online shopping festivals, it can provide scientific and effective marketing reference, and promote the sustainable development of online shopping festivals. This paper takes the “Double 11” online shopping festival as the research object. Based on the LDA+LSA+NMF integrated theme extraction model, kernel density analysis, grouping analysis and cluster outlier analysis in ArcGIS technology are adopted. We explore the evolution pattern of microblog users’ attention to the online shopping festival in the spatial and temporal dimensions. In the temporal dimension, the number of releases showed a stepwise increase, and concerns showed annual topic evolution and daily three-stage differential evolution. In the spatial dimension, the release volume showed a gradient decreasing trend from coastal to inland and from east to west, and concerns showed certain regional differences. The main contribution of this paper is to propose a funnel theme extraction model with multi-model integration, and provide a new perspective for the spatial research of online shopping festival based on ArcGIS spatial analysis technology.

Summary: To investigate the clinical characteristics and risk factors of specific human leukocyte antigen loss (HLA loss) in relapsed acute myeloid leukaemia (AML)/myelodysplastic syndrome (MDS) patients after allogeneic haematopoietic stem cell transplantation (allo‐HSCT), and compare the responses of patients with HLA loss relapse with those without HLA loss (non‐HLA loss) to different treatment regimens. Clinical data of traceable patients with AML/MDS after myeloablative allo‐HSCT in our centre between January 2010 and June 2021, who experienced disease relapse after the transplantation, were collected. The patients were divided into the HLA loss relapse group and the non‐HLA loss relapsed group based on HLA loss gene test findings by next‐generation sequencing. The patients' median overall survival (OS) after the relapse were compared, and univariate and multivariate analyses were performed using the Kaplan–Meier survival curve and Cox proportional hazard model to explore the responses to different treatments after relapse. A total of 2359 patients were selected. Retrospective HLA gene loss gene detection was performed for the deoxyribonucleic acid in 179 relapsed patients, including 47 patients in the HLA loss group (27.2%), 126 patients in the non‐HLA loss group (72.8%) and 6 patients were excluded due to a lack of confirmed results. There was no significant statistical difference in the baseline characteristics of patients between the two groups, but as to transplantation‐related characteristics, the donor–recipient relationship and HLA mismatched loci were statistically different between the two groups (both p < 0.001). Multivariate Cox analysis showed that more HLA mismatched loci ≥3 (HR = 3.66; 95% CI: 1.61–8.31; p = 0.002), time (≤6 months) from HSCT to relapse (HR = 7.92; 95% CI: 3.35–18.74; p < 0.001) and donor chimerism (CD3) in bone marrow at relapse (HR = 1.02; 95% CI: 1.00–1.03; p = 0.036) were independent factors affecting HLA loss relapse. The ratio of negative conversion of FLT3‐ITD or CEBPA mutation was significantly lower in patients with post‐transplantation HLA loss relapse than in the non‐HLA loss group (0.0% vs. 45.5%, p = 0.003; 0.0% vs. 80.0%, p = 0.035), with none of the patients with FLT3‐ITD or CEBPA mutation turned negative in the HLA loss group. The number of gene mutations turned negative when relapse in the non‐HLA loss group was remarkably higher than that in the HLA loss group (p = 0.001). Using donor lymphocyte infusion (DLI) could not prolong OS for the HLA loss group (p = 0.42). Nevertheless, second transplantation had a significant positive impact on OS in the HLA loss group (p = 0.017), although only five patients in the HLA loss group underwent second transplantation. However, patients in the non‐HLA loss group using DLI had a relatively longer OS time than those without DLI (p = 0.017). Second transplantation could also prolong OS in the non‐HLA loss group, but the effect was not as significant as in the HLA loss group (p = 0.053). In summary, HLA loss detection is essential for patients with recurrence after transplantation, especially for those with more HLA mismatched loci and non‐sibling donor. Furthermore, the detection of HLA loss has a guiding role in choosing subsequent therapy when relapsed, as secondary transplantation is more suitable than DLI for those with HLA loss. [ABSTRACT FROM AUTHOR]

Poly-γ-glutamic acid (γ-PGA) is an environment-friendly super absorbent polymer that can be used as a soil conditioner, which is promising to improve crop productivity and cope with soil degradation. The objectives of this study are to study the effects of γ-PGA on soil physicochemical properties and winter wheat (Triticum aestivum L. cv. Xinong 975) production in arid region of Northwest China. According to the mass ratio of γ-PGA and soil, experiment treatments consisted of four different γ-PGA application rates, which were designated as 0 (CK), 0.05% (P0.05), 0.1% (P0.1), and 0.15% (P0.15), respectively. The mixed soil samples were uniformly filled into identical plastic pots. Each treatment had three replicates randomly distributed within 12 pots. The results indicated that γ-PGA significantly increased saturated water content by 6.3-11.5%, field capacity by 8.4-15.3%, and plant available water by 5.1-12.5% compared with the CK. γ-PGA increased soil NO3−-N content and residue, and enhanced the proportions of soil macro-aggregates compared with the CK. γ-PGA increased winter wheat yield by 29.3-34.7%, and WUE by 21.2-33.3% compared with the CK. The main conclusion γ-PGA application amount of 0.05-0.1% can be used to improve soil physicochemical properties and winter wheat production in degraded soil. [ABSTRACT FROM AUTHOR]

Myeloproliferative neoplasms (MPNs) with concurrent BCR‐ABL1 fusion gene and CALR mutation are especially rare. We report a patient with coexisting BCR‐ABL1 fusion gene, CALR, and TET2 mutations who was treated with the combination of the second‐generation TKI nilotinib and JAK1/JAK2 inhibitor ruxolitinib. [ABSTRACT FROM AUTHOR]

In summary, we described two cases of patients with symptoms resembling APL carrying the recurrent I NUP98-RARG i fusion but lacking a response to ATRA and/or ATO induction. (A) Bone-marrow morphology of the patient at initial diagnosis; (B) bone-marrow morphology of the patient after one course of chemotherapy; (C) G-banded karyotyping of the patient with 46,XY,add(1)(p22),? Identification of a recurrent fusion NUP98-RARG in acute myeloid leukaemia resembling acute promyelocytic leukaemia Acute promyelocytic leukaemia (APL) is a distinctive acute myeloid leukaemia (AML) subtype, which is triggered by a I PML i - I RARA i fusion caused by t(15,17)(q24;q21) translocation; the I PML i - I RARA i fusion has been proved to be a typical genetic marker in about 95% of the cases ofAPL.1 Recently, more and more cases of a morphology resembling APL carrying I RARG i fusions ( I NUP98-RARG i , I PML i - I RARG i , I CPSF6 i - I RARG i , I NPM1 i - I RARG i - I NPM1 i and I HNRNPC i - I RARG i ) without I RARA i rearrangements have been reported.2-6 I RARG i (retinoic acid receptor ), whose gene is located at chromosome 12q13, belongs to the RAR family, and acts as one of the retinoic acid receptors, and is highly homologous (90%) with RARA (retinoic acid receptor ) and RARB (retinoic acid receptor ).7 I RARA i -associated fusions are known to be associated with APL or atypical APL, but I RARG i fusions are rare. [Extracted from the article]

ETO2 is a nuclear co‐repressor, which plays a critical role in the regulation of the cell cycle, self‐renewal capacity, and differentiation of hematopoietic progenitor cells. We identified novel fusion transcripts involving ETO2 and CTCF by RNA‐seq in a multiple relapsed AML case. The CTCF‐ETO2 and ETO2‐CTCF chimeric genes were validated by RT‐PCR and Sanger sequencing. In addition, both transcripts apparently promoted cell proliferation via JAK/STAT3 pathway that is sensitive to STAT3 inhibitors. The novel fusions may have prognostic value and pathogenic mechanisms in acute myeloid leukemia. [ABSTRACT FROM AUTHOR]